Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Neurology Neurosurgery & Psychiatry

• Publication date

  1998-03-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1136/jnnp.64.3.314PMID 9527140PMCID PMC2170010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease

  1997cited by this paper
• Pathophysiology of movement disorders studied using PET.

  1997cited by this paper
• Physiologic modeling of PET data: quantitative conflict and challenge.

  1997cited by this paper
• Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials.

  1997cited by this paper
• An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

  1996cited by this paper
• Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-Dopa PET in Parkinson's disease.

  1996cited by this paper
• Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease.

  1996cited by this paper
• Calculating correlation coefficients with repeated observations: Part 2—correlation between subjects

  1995cited by this paper
• Clinical and [18F] dopa PET findings in early Parkinson's disease.

  1995cited by this paper
• Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects.

  1994cited by this paper
• Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism

  1994cited by this paper
• Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations.

  1994cited by this paper
• The effect of entacapone (OR‐611) on brain [18F]‐6‐L‐fluorodopa metabolism

  1994cited by this paper
• Extrapyramidalism in Alzheimer's disease: prevalence, psychiatric, and neuropsychological correlates.

  1994influential reference
• Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels

  1993cited by this paper
• When does Parkinson's disease begin?

  1992cited by this paper
• Ageing and Parkinson's disease: substantia nigra regional selectivity.

  1991cited by this paper
• The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.

  1990influential reference
• Striatal function in normal aging: Implications for Parkinson's disease

  1990cited by this paper
• Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

  1988cited by this paper
• The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

  1988cited by this paper
• Aetiology of Parkinson's disease.

  1983cited by this paper
• Parkinsonism

  1967cited by this paper
• The Analysis of Variance

  1960cited by this paper

• Beyond nigrostriatal dopamine transporter loss: whole-brain DAT depletion patterns discriminate PD phenotypes.

  2026cites this paper
• Genetic and Pathological Testing Attitudes for Parkinson's Disease in At-Risk Relatives.

  2026cites this paper
• Beyond Symptoms: WHODAS as a Biopsychosocial Measure to Complement Functioning Assessment in Parkinsons Disease

  2025cites this paper
• Development of Positron Emission Tomography Radiotracers for Imaging α-Synuclein Aggregates

  2025cites this paper
• Balancing practicality and complexity in neuroimaging models of Parkinson’s disease progression

  2025cites this paper
• Nuclear Medicine Imaging Biomarkers in Parkinson’s Disease: Past, Present, and Future Directions

  2025cites this paper
• Nigral volume loss in prodromal, early, and moderate Parkinson’s disease

  2025cites this paper
• Parkinson's disease progression is shaped by longitudinal changes in cerebral compensation

  2025cites this paper
• Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression

  2025cites this paper
• Longitudinal Trajectory of Dopamine and Serotonin Transporters in Parkinson Disease

  2025cites this paper
• Neuroimaging Biomarkers in Parkinson's Disease.

  2024cites this paper
• Parkinson's disease progression is multifaceted: Evidence for the underlying benchmarks.

  2024cites this paper
• Clinical significance of MRI-measured olfactory bulb height as an imaging biomarker of idiopathic Parkinson’s disease

  2024cites this paper
• Nigral volume loss in prodromal, early, and moderate Parkinson’s disease

  2023cites this paper
• Serial deep gray nuclear DTI changes in Parkinson’s disease over twelve years

  2023cites this paper
• Charting Disease Trajectories from Isolated REM Sleep Behavior Disorder to Parkinson's Disease

  2023cites this paper
• Role of Functional Neuroimaging with 123I-MIBG and 123I-FP-CIT in De Novo Parkinson’s Disease: A Multicenter Study

  2023cites this paper
• Imaging Markers in Genetic Forms of Parkinson’s Disease

  2023cites this paper
• Dopamine and vesicular monoamine transport loss supports incidental Lewy body disease as preclinical idiopathic Parkinson

  2023cites this paper
• Striatal Dopamine Loss in Early Parkinson's Disease: Systematic Review and Novel Analysis of Dopamine Transporter Imaging

  2023cites this paper
• Relevance of 18F-DOPA visual and semi-quantitative PET metrics for the diagnostic of Parkinson disease in clinical practice: a machine learning-based inference study

  2023cites this paper
• Using 18F-AV-133 VMAT2 PET Imaging to Monitor Progressive Nigrostriatal Degeneration in Parkinson Disease

  2023cites this paper
• Estimating the sequence of biomarker changes in Parkinson's disease.

  2023cites this paper
• Clinical severity in Parkinson’s disease is determined by decline in cortical compensation

  2023cites this paper
• Dopaminergic Input Regulates the Sensitivity of Indirect Pathway Striatal Spiny Neurons to Brain-Derived Neurotrophic Factor

  2023cites this paper
• Spontaneous Partial Recovery of Striatal Dopaminergic Uptake Despite Nigral Cell Loss in Asymptomatic MPTP-Lesioned Female Minipigs.

  2022cites this paper
• Production of [11C]Carbon Labelled Flumazenil and L-Deprenyl Using the iMiDEV™ Automated Microfluidic Radiosynthesizer

  2022cites this paper
• Ameliorating potential of curcumin and its analogue in central nervous system disorders and related conditions: A review of molecular pathways

  2022cites this paper
• In vivo18F-DOPA PET imaging identifies a dopaminergic deficit in a rat model with a G51D α-synuclein mutation

  2022cites this paper
• Temporal trajectory model for dopaminergic input to the striatal subregions in Parkinson's disease.

  2022cites this paper
• [Development of early diagnosis of Parkinson's disease and comprehensive economic analysis of the effect of its implementation].

  2021cites this paper
• Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism

  2021cites this paper
• Targeted attenuation of elevated histone marks at SNCA alleviates α‐synuclein in Parkinson's disease

  2021cites this paper
• Characterizing mild cognitive impairment in prodromal Parkinson’s disease: A community‐based study in China

  2021influential citation
• α-Synuclein Overexpression Increases Dopamine D2/3 Receptor Binding and Immune Activation in a Model of Early Parkinson’s Disease

  2021cites this paper
• Neuroprotection and Neurorestoration of Nigra Striatal Dopamine Neurons by Novel Multitarget Drugs, M30

  2021cites this paper
• Parkinsonism

  2021cites this paper
• Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease

  2021cites this paper
• Methodological considerations of evaluating the rate of presynaptic dopaminergic denervation in Parkinson disease with radiotracers

  2021cites this paper
• Parkinson’s disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI

  2021cites this paper
• Dopamine transporter (DAT) imaging in Parkinson’s disease and related disorders

  2021cites this paper
• Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease

  2021cites this paper
• Gait and Balance Changes with Investigational Peripheral Nerve Cell Therapy during Deep Brain Stimulation in People with Parkinson’s Disease

  2021cites this paper
• Serial DaT‐SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years’ follow‐up

  2021cites this paper
• The role of neuroimaging in Parkinson’s disease

  2021cites this paper
• Positron Emission Tomography

  2020cites this paper
• Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder

  2020cites this paper
• Imaging of dopamine transporters in Parkinson disease: a meta‐analysis of 18F/123I‐FP‐CIT studies

  2020cites this paper
• Effects of L-DOPA on gene expression in the frontal cortex of rats with unilateral lesion of midbrain dopaminergic neurons

  2020cites this paper
• Clinical and Imaging Progression in the PARS Cohort: Long‐Term Follow‐up

  2020cites this paper
• Elevated caudate connectivity in cognitively normal Parkinson’s disease patients

  2020cites this paper
• Characteristics of Writing in Parkinson’s Disease: Focused on Pen Pressure, Letter Size, and Writing Speed

  2020cites this paper
• Parkinson’s Disease

  2020cites this paper
• Quantitative Assessment of Gait and Balance Following Deep Brain Stimulation in Patients with Parkinson’s Disease

  2020cites this paper
• Brain iron deposition is linked with cognitive severity in Parkinson’s disease

  2020cites this paper
• Targeted attenuation of elevated histone marks at SNCA alleviates α-synuclein in Parkinson’s disease

  2020cites this paper
• Effects of L-DOPA on Gene Expression in the Frontal Cortex of Rats with Unilateral Lesions of Midbrain Dopaminergic Neurons

  2020cites this paper
• Simplified quantification of [18F]FE-PE2I PET in Parkinson’s disease: Discriminative power, test–retest reliability and longitudinal validity during early peak and late pseudo-equilibrium

  2020cites this paper
• A Method for the Prediction of Clinical Outcome Using Diffusion Magnetic Resonance Imaging: Application on Parkinson’s Disease

  2020cites this paper
• Continuous Real-World Gait Monitoring in Idiopathic REM Sleep Behavior Disorder

  2019cites this paper
• Risk of Parkinson’s disease after colectomy: longitudinal follow-up study using a national sample cohort

  2019cites this paper
• QUANTITATIVE NUCLEAR MEDICINE IMAGING USING ADVANCED IMAGE RECONSTRUCTION AND RADIOMICS

  2019cites this paper
• 18F-DOPA

  2019cites this paper
• Позитронная эмиссионная и однофотонная эмиссионная компьютерная томография в оценке состояния моноаминергических систем мозга при экстрапирамидных расстройствах

  2019cites this paper
• Gait analysis with wearables predicts conversion to Parkinson disease

  2019cites this paper
• Advances in the Research of Risk Factors and Prodromal Biomarkers of Parkinson's Disease.

  2019cites this paper
• PET and SPECT in the assessment of monoaminergic brain systems in extrapyramidal disorders

  2019cites this paper
• Sleep in Parkinson’s disease

  2019cites this paper
• Spiny Projection Neuron Dynamics in Toxin and Transgenic Models of Parkinson’s Disease

  2019cites this paper
• In Vivo Positron Emission Tomography of Extrastriatal Non-Dopaminergic Pathology in Parkinson Disease

  2018cites this paper
• Is the Timed Up and Go (TUG) Sensitive to Differentiating Patients with Mild to Moderate PD Compared to Age Matched Controls: A Descriptive Pilot Study

  2018cites this paper
• The Neuroimaging of Brain Diseases: Structural and Functional Advances

  2018influential citation
• Diagnostic and prognostic aspects of clinical brain dopamine transporter imaging in parkinsonism

  2018cites this paper
• Autonomic dysfunction and white matter microstructural changes in drug-naïve patients with Parkinson’s disease

  2018cites this paper
• 11C‐PE2I and 18F‐Dopa PET for assessing progression rate in Parkinson's: A longitudinal study

  2018cites this paper
• Conditioning Against the Pathology of Parkinson's disease.

  2018cites this paper
• PET Imaging in Movement Disorders.

  2018cites this paper
• Structural and Functional MRI in Familial Parkinson's Disease.

  2018cites this paper
• Imaging Transplantation in Movement Disorders.

  2018cites this paper
• Biomarkers in Parkinson disease: studies on clinical, radiological and biological biomarkers

  2018cites this paper
• Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease.

  2018cites this paper
• Incidence of Parkinson’s disease in a large patient cohort with idiopathic smell and taste loss

  2018cites this paper
• Deregulation of &agr;‐synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA

  2017cites this paper
• Association of serum Aβ1-42, cystatin C and UA with parkinson's disease

  2017cites this paper
• Medical Treatment of Parkinson’s Disease

  2017cites this paper
• Neuroprotection of Granulocyte Colony-Stimulating Factor for Early Stage Parkinson's Disease

  2017cites this paper
• Are rodent models of Parkinson's disease behaving as they should?

  2017cites this paper
• Movement Disorders Curricula

  2017influential citation
• Cognitive changes in prodromal Parkinson's disease: A review

  2017cites this paper
• Medication Side Effect Profiles in PD Patients in a Safety-Net Hospital

  2017cites this paper
• DAPHNE: A Novel e-Health System for the Diagnosis and the Treatment of Parkinson's Disease

  2017cites this paper
• Neuroimaging in pre-motor Parkinson's disease

  2017influential citation
• Neuroimaging of Movement Disorders

  2017cites this paper
• Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study.

  2017cites this paper
• Loss of gait control assessed by cognitive-motor dual-tasks: pros and cons in detecting people at risk of developing Alzheimer’s and Parkinson’s diseases

  2017cites this paper
• Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment

  2017cites this paper
• Clioquinol Improves Cognitive, Motor Function, and Microanatomy of the Alpha-Synuclein hA53T Transgenic Mice.

  2016cites this paper
• Advances in markers of prodromal Parkinson disease

  2016cites this paper
• Neurologische und dementielle Erkrankungen

  2016cites this paper
• The role of biomarkers and imaging in Parkinson’s disease

  2016cites this paper